Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk at the start of treatment.
Givinostat (also known by its brand name Duvyzat) was approved for market authorisation by UK’s MHRA in December 2024, for those aged 6+. It was also recommended for approval by the European Medicines Agency (EMA) in April 2025, for those who are aged 6+, ambulant, and who are being treated with steroids.
Our friends at Duchenne UK played a key role in the assessment of givinostat, working alongside other patient groups to represent the Duchenne community throughout the process. Click here to read their announcement.
Produced by Italfarmaco, givinostat is taken as an oral suspension twice daily. It is a type of treatment known as an HDAC inhibitor, which reduces muscle inflammation and fibrosis. HDAC inhibitors also promote muscle regeneration and slow the progression of Duchenne.
Givinostat is currently under review by the UK’s National Institute for Health and Care Excellence (NICE) as to whether it will be approved for use in NHS England. NICE held its initial committee meeting to appraise the drug in July, with a decision provisionally expected in September. However, to the disappointment of the Duchenne community, in August NICE announced it would seek further guidance at a second committee meeting in October. Read the full story here.